1 Anti-tRNA synthetase syndrome interstitial lung disease: A single center experience

2

3 Authors:

- 4 Erin M. Wilfong, M.D., Ph.D.^{1,2†}, ORCID ID 0000-0002-6584-1578
- 5 Jennifer J. Young-Glazer, M.D., M.S.C.I², ORCID ID 0000-0002-3265-9112
- 6 Bret K. Sohn, MD²
- 7 Gabriel Schroeder, M.D.³
- 8 Narender Annapureddy, M.D.², ORCID ID 0000-0002-4012-3406
- 9 Erin A. Gillaspie, M.D.⁴, ORCID ID 0000-0003-2075-5534
- 10 April Barnado, M.D., M.S.C.I.², ORCID ID 0000-0002-9573-4335
- 11 Leslie J. Crofford, M.D.², ORCID ID 0000-0002-6347-5738
- 12 Rosemarie Beckford Dudenhofer, M.D.¹
- 13

14 Affiliations:

- ¹⁵ ¹Vanderbilt University Medical Center, Department of Medicine, Division of Allergy, Pulmonary, and
- 16 Critical Care Medicine, Nashville, TN, 37232, USA
- ¹⁷²Vanderbilt University Medical Center, Department of Medicine, Division Rheumatology and
- 18 Immunology, Nashville, TN, 37232, USA
- ¹⁹ ³Vanderbilt University Medical Center, Department of Medicine, Nashville, TN, 37232, USA
- ⁴Vanderbilt University Medical Center, Department of Thoracic Surgery, Nashville, TN 37232
- 21
- ¹Corresponding Author:
- 23 Erin M. Wilfong, M.D., Ph.D.
- 24 1161 21st Ave So., MCN T-1218
- 25 Nashville, TN 37232
- 26 Phone: (615) 936-5747

- 27 Fax: (615) 322-6248
- 28 Email: erin.m.wilfong@vumc.org

29 Abstract:

30 Background: Recognition of Anti tRNA synthetase (ARS) related interstitial lung disease (ILD) is key 31 to ensuring patients have prompt access to immunosuppressive therapies. The purpose of this 32 retrospective cohort study was to identify factors that may delay recognition of ARS-ILD. 33 Methods: Patients seen at Vanderbilt University Medical Center (VUMC) between 9/17/2017-34 10/31/2018 were included in this observational cohort. Clinical and laboratory features were obtained 35 via chart abstraction. Kruskal-Wallis ANOVA, Mann-Whitney U, and Fisher's exact t tests were utilized 36 to determine statistical significance. 37 Results: Patients with ARS were found to have ILD in 51.9% of cases, which was comparable to the frequency of ILD in systemic sclerosis (59.5%). The severity of FVC reduction in ARS (53.2%) was 38 comparable to diffuse cutaneous systemic sclerosis (56.8%, p=0.48) and greater than dermatomyositis 39 40 (66.9%, p=0.005) or limited cutaneous systemic sclerosis (lcSSc, 71.8%, p=0.005). Frank 41 honeycombing was seen with ARS antibodies but not other myositis autoantibodies. ARS patients were 42 more likely to first present to a pulmonary provider in a tertiary care setting (53.6%), likely due to fewer 43 extrapulmonary manifestations. Only 33% of ARS-ILD were anti-nuclear antibody, rheumatoid factor, 44 or anti-cyclic citrullinated peptide positive. Patients with ARS-ILD had a two-fold longer median time to 45 diagnosis compared to other myositis-ILD patients (11.0 months, IQR 8.5 to 43 months vs. 5.0 months, IQR 3.0 to 9.0 months, p=0.003). 46

47 Conclusions: ARS patients without prominent extra-pulmonary manifestations are at high risk for not
 48 being recognized as having a connective tissue disease related ILD and miscategorized as UIP/IPF
 49 without comprehensive serologies.

50 Keywords:

- 51 Idiopathic inflammatory myopathies
- 52 Anti-tRNA synthetase syndrome
- 53 Systemic sclerosis
- 54 Connective tissue disease related interstitial lung disease
- 55 Usual interstitial pneumonia

57 Recognition of idiopathic inflammatory myopathy (IIM) spectrum disease is challenging due 58 phenotypic heterogeneity. While the original Bohan and Peter criteria focused on classic skin rashes 59 and muscle weakness [1], there has been increasing recognition that these clinical classifications oversimplify marked heterogeneity and that myositis autoantibodies are associated with a variety of 60 61 classical clinical presentations (table 1). Interstitial lung disease is particularly prevalent in the antitRNA synthetase syndrome (ARS), which classically presents with the triad of arthritis, interstitial lung 62 63 disease, and mechanic's hands. Amongst ARS antibodies, however, the frequency of skin, muscle, 64 and lung disease is variable. Patients with anti-Jo-1 antibodies are more likely to have joint and muscle 65 involvement; non-Jo-1 positive patients are more likely to have vascular and cutaneous involvement [2]. Patients with anti-PL7 and anti-PL12 antibodies have more severe pulmonary manifestations [3]. 66 67 The diagnosis of IIM-ILD remains a challenge. Presently, the American Thoracic Society 68 recommends that CTD-ILD be ruled out clinically and with basic serologic screening (anti-nuclear 69 antibodies (ANA), rheumatoid factor (RF), and anti-cyclic citrullinated antibodies (CCP)), but does not 70 recommend comprehensive myositis serologies [4]. However, not only are basic serologies more apt to 71 be negative in IIM compared other connective tissue diseases, but IIM patients are also less likely to 72 fulfil clinical connective tissue disease (CTD) classification criteria. For example, nearly all patients with 73 SSc-ILD will have a positive ANA, and the clinical classification criteria for SSc have >95% sensitivity in 74 external validation cohorts [5]. In contrast, fewer than 50% of ARS patients have a positive ANA [6], 75 and external validation of the 2017 American College of Rheumatology and European League Against 76 Rheumatism (ACR/EULAR) classification criteria for idiopathic inflammatory myopathies cohorts has 77 vielded sensitivities as low as 71% [7]. For non-Jo1 associated ARS, the sensitivity of the 2017 ACR/EULAR classification criteria is as low as 25% [8]. This low sensitivity has led to the ACR/EULAR 78 79 funding the CLASS (classification criteria of antisynthetase syndromes) project to develop improved 80 criteria to diagnose of ARS [9].

The goal of this retrospective cohort study was to (1) evaluate the clinical, radiographic, and serologic features of ARS compared to other patients with IIM and SSc, and (2) gain insights into

- possible etiologies leading to delayed diagnosis and therapy in the ARS subgroup. We hypothesize
 that ARS patients will have more subtle clinical and laboratory findings compared to other subsets of
 IIM-ILD and SSc-ILD despite an equivalent physiologic severity of ILD.
- 86

87 Patients and Methods

88 Patient Identification

89 Institutional Review Board approval was obtained. Patients were identified from either the Myositis 90 and Scleroderma Treatment Initiative Center (MYSTIC) cohort or the ILD in Autoimmune Inflammatory 91 Myopathy Cohort (IAIMC). Patients with suspected systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, or interstitial pneumonia with autoimmune features were 92 eligible for referral to the MYSTIC cohort by their treating provider in the outpatient pulmonary, thoracic 93 94 surgery, or rheumatology clinic, the inpatient rheumatology or pulmonary consulting service, or by their 95 critical care provider in the intensive care unit (VUMC IRB 141415) from September 20, 2017-96 December 31, 2019. As MYSTIC is a longitudinal convenience cohort, additional patients were 97 identified through the electronic medical record (VUMC IRB 180672) using a keyword search of the 98 following: "dermatomyositis", "polymyositis", "anti-synthetase syndrome", "systemic sclerosis" in any 99 Vanderbilt Rheumatology or Pulmonology affiliated practice visit between July 1, 2018-October 31, 2018. Exclusion criteria included prior inclusion in the MYSTIC cohort and myositis attributed to 100 101 medications, infection, or another rheumatologic condition (e.g. mixed connective tissue disease. Diagnoses were verified by review of progress notes, laboratory findings, and scanned documents. 102

103

104 Clinical phenotyping

105 Clinical phenotyping was performed by chart abstraction to identify date of symptom onset, skin 106 manifestations (digital ulceration/pitting, mechanic's hands, Gottron's sign/papules, heliotrope rash, 107 shawl sign, skin ulcerations), Raynaud's phenomenon, inflammatory arthritis, pulmonary manifestations 108 (ILD, pulmonary arterial hypertension), myocarditis, muscle weakness, esophageal dysmotility and/or

109 reflux. Serologic data collected included ANA titer and pattern, RF, anti-CCP, and comprehensive 110 myositis serologies (Jo-1, PL-7, PL-12, EJ, OJ, SRP, Mi-2, P155/140, Tif-1y, SAE1, MDA-5, NXP-2, Ro52, Ro60, Pm/Scl-100, U3RNP, U2RNP through ARUP, Salt Lake, UT). Data on cytoplasmic ANA 111 112 antibodies was not routinely available. Laboratory values for creatinine kinase (CK) were recorded 113 when available. Patients with dermatomyositis or polymyositis met the 2017 ACR/EULAR classification criteria for probable or definite dermato- or polymyositis [10]. Patient with ARS met the diagnostic 114 115 criteria proposed by Connors et al. [11] but were not required to meet the 2017 IIM classification 116 criteria. SSc patients met the 2013 classification criteria [12]. When documenting first point of contact 117 at VUMC, patients presenting to thoracic surgery were classified as having presented to a pulmonary provider. Basic demographic data such as age, self-identified gender, and self-identified race/ethnicity 118 119 were also collected.

120

121 Pulmonary phenotyping

122 Pulmonary phenotyping was performed using chart abstraction and analysis of computerized tomography (CT) scans, chest x-ray, PFTs, echocardiogram, right heart catheterization (RHC), and 123 124 pathology reports. Patients were classified as having interstitial lung disease if the radiologist reading 125 the clinical CT scan determined that fibrosis or interstitial lung disease was present on CT scan or chest x-ray if CT was unavailable. The severity of restriction or reduction in DLCO was graded as mild (65-126 127 79% predicted), moderate (50-64% predicted) or severe (<50% predicted) using the worst available PFT value. Patients were classified as having pulmonary hypertension if an echocardiogram 128 demonstrated RVSP > 40 mmHg or mean PA pressure on RHC >25 mmHg. RHC was considered gold 129 130 standard in cases of conflicting data. CT reports were analyzed for mention of honeycombing, bronchiectasis, or ground glass opacities. Radiographic classifications of ILD, e.g. usual interstitial 131 132 pneumonia (UIP), atypical for UIP, nonspecific interstitial pneumonia (NSIP), and organizing pneumonia (OP) as determined by the reading radiologist was recorded. Patients for whom no CT or PFTs were 133 obtained were assumed to have no or mild ILD [13, 14]. 134

135

136 Statistics

All available cases were analyzed. Bias was minimized through blinding during chart abstractions. 137 138 Missing data was addressed through pairwise deletion. Categorical variables were analyzed using 139 Fisher's exact test through the GraphPad Quick Calcs Web site: http://www.graphpad.com/guickcalcs/ 140 (accessed November 2020). Differences in continuous variables were tested using Kruskal-Wallis 141 ANOVA for multiple comparisons followed by Mann-Whitney U tests for comparisons between groups in GraphPad Prism v.7.04. All analyses were two-tailed, and p values of less than 0.05 were 142 143 considered statistically significant. Data is reported as the average ± standard error of the mean unless otherwise noted. 144 145 146 Results 147 Demographics 148 Demographic characteristics are shown in Table 2. One hundred twenty-five patients were 149 included in the study; one patient was excluded due to conflicting historical reports regarding the 150 presence of ILD and the lack of any PFTs or CT scans. Eighty-four patients (20 DM, 4 PM, 16 ARS, 14 151 dcSSc, 30 lcSSc) were included from the prospective MYSTIC cohort; 40 unique patients were included 152 from electronic IAIMC cohort (17 DM, 8 PM, 12 ARS, 2 dcSSc, 1 lcSSc). Subjects were predominantly 153 female (77.9% IIM, 78.7% SSc) and Caucasian (81.8% IIM, 78.7% SSc). Median disease duration was 154 estimated from the first report of symptom onset to cohort enrolment and was 5.2 years for IIM versus

155 9.5 years in SSc (p=0.007).

156

157 Clinical phenotypes in IIM

158 Clinical characteristics of IIM patients are shown in Table 3. Thirty-seven patients (48.1%) were

159 classified as DM, 12 (15.5%) were classified as PM, and 28 (36.4%) were diagnosed as ARS.

160 Subjective proximal muscle weakness was less common in ARS (64.3%) than PM (100%, p=0.002) but

161	not DM (73.0%, p=0.09). There was no difference in the frequency of muscle enzyme elevation in ARS
162	(75.0%) compared to DM (78.3%, p=0.77) or PM (91.7%, p=0.40). Dysphagia or GERD was present in
163	46.4% of ARS patients, which was not statistically different from DM (29.8%, p=0.20) or PM (66.7%,
164	p=0.31). Inflammatory arthritis was noted in 60.7% of ARS patients, which is higher than either DM
165	(27.0%, p=0.01) or PM (8.3%, p=0.004). By convention, cutaneous manifestations are absent in
166	polymyositis. There was a lower prevalence of Gottron's sign/papules or heliotrope rash in ARS
167	compared to DM (21.4% v. 89.1%, p=0.0001). There was no difference in prevalence between ARS
168	and DM of mechanic's hands (43.8% v. 24.3%, p=0.18) or Raynaud's phenomenon (37.8% v. 35.7%,
169	p=1.0).
170	Known interstitial lung disease was present in 51.9% of IIM patients. Chest CT scans were
171	available for all but two IIM-ILD patients. ILD was more frequently seen in ARS (78.5%) than in
172	dermatomyositis (40.5%, p=0.00263) or polymyositis (25.0%, p=0.003). In this cohort, all patients with
173	PL-7, PL-12, or EJ antibodies had interstitial lung disease; 80% of Jo-1 positive patients had ILD.
174	Patients with Mi-2 associated dermatomyositis had the lowest frequency of ILD with only 20.0% having
175	known ILD.
176	Serologically, only 36% of ARS patients were ANA positive compared to 80.6% of DM patients
177	(p=0.004) and 60% of PM patients (p=0.45). Ro52 positivity was observed with similar frequency in
178	ARS and DM (63.6% v.40.0%, p=1.00) but no PM patient was Ro52 positive. There was no statistically
179	significant difference in the frequency of RF positivity.
180	
181	Patients with ARS-ILD frequently present to pulmonary providers at a tertiary center
107	Of APS nationts, 52.6% procented first to pulmonany providers, which is significantly higher than

Of ARS patients, 53.6% presented first to pulmonary providers, which is significantly higher than DM (16.2%, p=0.003) or PM (8.3%, p=0.01). There was no difference in the likelihood of Jo-1 or non-Jo1 associated ARS to present first to a pulmonary provider (60.0% v. 75.0%, p=0.65). Of the 15 patients with ARS-ILD who presented initially to pulmonology, 80% of patients had been seen by outside pulmonologists and 40% by outside rheumatologists. Only one had received the correct

diagnosis of ARS-ILD prior to tertiary referral. The time from symptom onset to diagnosis could be
abstracted for 21/22 ARS-ILD patients, 11/15 DM-ILD patients, and 3/3 PM-ILD patients. Patients with
ARS-ILD had a longer median time to diagnosis (11.0 months, IQR 8.5 to 43 months) than other IIMILD subsets (5.0 months, IQR 3.0 to 9.0, p=0.003). (Figure 1) There was a trend towards ARS-ILD
patients presenting to pulmonary clinic being less likely to meet IIM classification criteria, but this did
not reach significance (66.7% v. 85.8%, p=0.6158).

Many pulmonary providers will screen for CTD-ILD using an ANA, RF, and anti-CCP antibodies. The efficacy of detecting a potential CTD-ILD with a basic serologic assessment using ANA, RF, and anti-CCP testing is shown in table 4. Patients with ARS-ILD were much less likely to be identified using this strategy than DM-ILD (33.3% v. 86.7%, p=0.002). If a CK was also obtained, the likelihood of detecting a possible CTD-ILD increased to 72.7% for ARS-ILD compared to 86.7% for DM-ILD (p=0.43). Statistical comparisons to PM-ILD were precluded due to small sample size. Myositis specific serologies were required to detect the final 27.3% of patients with ARS-ILD.

200

201 Radiographic features of ARS-ILD

202 Radiographic features of IIM and SSc associated ILD are shown in table 5. Due to the paucity of 203 PM-ILD, these were excluded from statistical comparisons. Notably, only patients with anti-tRNA 204 synthetase antibodies (22.7%) had CT scans that were read by a radiologist as compatible with usual 205 interstitial pneumonia (UIP); no patient a non-anti-tRNA synthetase antibody had a CT scan compatible 206 with UIP. The solitary patient with clinical dermatomyositis and a UIP pattern CT scan did not have 207 comprehensive myositis serologies. Patients with UIP pattern CT scans ranged in age from 49.2 to 70.8 years of age and there was a trend towards the median age of UIP-pattern patients being older 208 209 than non-UIP pattern patients (63.3, IQR 54.8,70.8 yrs., v. 55.2, IQR 46.8,60.6 yrs., p=0.09). 210 Bronchiectasis trended towards being more prevalent in ARS compared to other IIM subsets (50% v. 211 22.2%, p=0.10). Of ARS patients, 13.6% had frank honeycombing, which was not seen an any other

IIM subset. There was no difference in the frequency of ground glass abnormalities between ARS andother IIM patients.

- 214
- 215 Physiologic features of ARS-ILD.

216 Physiologic features of IIM- and SSc- ILD are shown in Figures 2 and 3. Due to the paucity of PM 217 patients with ILD, these were again excluded from subgroup statistical analyses. Overall, patients with 218 IIM and SSc had comparable restriction (60.3% v. 66.6% predicted FVC, p=0.15) and diffusion 219 impairment (48.0% v. 51.1% predicted DLCO, p=0. 63). However, ARS-ILD demonstrated more severe reduction in FVC (53.2% predicted) than patients with DM (66.9% predicted, p=0.005) or IcSSc (71.8% 220 predicted, p=0.005). The severity of ARS and dcSSc-ILD was comparable (53.2% v. 56.8% predicted 221 222 FVC, p=0.48). Similarly, patients with ARS were more likely to have a severe diffusion impairment 223 (e.g. <50% predicted) than in DM (54.5% v. 6.7%, p=0.004) but not dcSSc (54.5% v. 30.0%, p=0.27). 224 While there was a trend towards worsening impairment of diffusion in ARS relative to DM (39.8% v. 225 48.0% predicted DLCO, p=0.08) and dcSSc (39.8% v. 51.4% predicted DLCO, p=0.13), this did not 226 reach statistical significance. There was no difference in the severity of restriction or diffusion 227 impairment ARS-ILD patients with positive vs. negative Jo-1 antibodies. 228

229 Discussion

230 Our primary findings can be summarized as following, (1) patients with ARS have a high frequency of interstitial lung disease with more severe restriction than other IIM subsets (2) radiographic UIP was 231 232 observed only in patients with ARS-ILD in this cohort, (3) patients with ARS are frequently referred to a 233 tertiary center after seeing a local pulmonologist and/or rheumatologist without receiving the correct diagnosis, and (4) patients with ARS-ILD have a delayed diagnosis compared to DM-ILD and PM-ILD. 234 235 Improving recognition of ARS-ILD is key to ensuring these patients have prompt access to 236 immunosuppressive therapies. Diagnostic delays in ARS are well described and are known to be an 237 independent risk factor for mortality in ARS-ILD [2]. Cavagna et al. described Jo-1 positive patients

who presented without the classic triad of arthritis, myositis, and interstitial lung disease had a trend
towards increased median time to diagnosis from 2.5 to 10 months [15]. While delays in ARS-ILD
diagnosis are frequently discussed in the literature, to our knowledge this is the first report to quantify a
delay in diagnosis in ARS-ILD compared to other IIM-ILD. Given that nearly 25% of ARS patients
present first with ILD [2], decreasing the diagnostic delay is critical.

243 The frequency with which ARS-ILD presents with UIP radiographically further complicates 244 recognition of ARS-ILD. In our cohort, 22.7% of patients had CT scans read as compatible with UIP. 245 While ARS-UIP may be enriched at an academic center, it has previously been recognized that most 246 IIM-UIP is associated with ARS. Of the 43 patients in the Pittsburgh cohort with biopsy proven UIP, only one did not have ARS [16]. Using the 2013 Fleischner Society guidelines, a cohort of 69 Chinese 247 248 ARS-ILD patients identified that 8.7% had a high resolution CT scan classified as UIP [17]. A second 249 longitudinal study of serial CT scans in ARS-ILD found that while 100% of patients had some ground 250 glass at diagnosis, subsequent scans showed the ground glass decreased in 38%. Additionally, 42% 251 of patients had honeycombing and 50% had worsening traction bronchiectasis at follow-up [18]. The 252 prevalence of honeycombing and traction bronchiectasis in ARS may lead to radiographic classification 253 as UIP on CT scans, especially in the community setting. The 2018 American Thoracic Society 254 guidelines for diagnosing idiopathic pulmonary fibrosis allow patients with ground-glass opacities to be 255 classified as UIP in the absence of other clear etiologies and so long as the ground-glass opacities are 256 not the predominant radiographic feature [4]. Thus, ARS patients without prominent extra-pulmonary manifestations are at high risk for not being recognized as having an alternative etiology and 257 258 miscategorized as UIP/IPF in the absence of comprehensive serologies.

In our cohort, only 33% of patients were identified on basic screening serologies to have signs of a connective tissue disease. While this is slightly lower than some prior studies [6, 17], a substantial number of ARS patients are ANA, RF, and anti-CCP negative in all cohorts. Additionally, there is increasing evidence that obtaining comprehensive serologies and engaging rheumatology improves the care of ILD patients. Nakashima et al. evaluated the ARS serology status of 168 patients with

idiopathic interstitial pneumonia and found that 10.7% were positive for an anti-tRNA synthetase
antibody, including 5.3% of patients who were diagnosed as IPF [19]. Another study found that even a
modest expansion of routine serologies and inclusion of a rheumatologist in the multi-disciplinary ILD
team resulted in 21% of IPF patients being re-classified as having an autoimmune process and eight
invasive diagnostic procedures were avoided [20]. This study further highlights the importance of using
expanded serologies to aid in the identification of IIM-ILD generally and ARS-ILD specifically.

270 Prompt recognition of ARS-ILD is imperative as immunosuppression is efficacious in ARS-ILD.

271 Previous work by Danoff and co-workers demonstrated that patients with IIM-ILD have an improvement

in their FVC following treatment with immunosuppressive therapy [21]. A post-hoc analysis of the

273 rituximab in myositis phase III clinical trial [22] indicated a benefit in ARS-ILD. Efficacy for tacrolimus in

usual interstitial pneumonia, which is nearly always ARS-ILD, have a slower rate of FVC decline and

both naïve [23] and refractory IIM-ILD [24] has also been reported. Even patients with myositis related

improved mortality compared with IPF patients after treatment with immunosuppression [16]. However,

if a patient is not recognized to have ARS-ILD, they may not gain access to critically needed

immunosuppressive agents. For this reason, we continue to advocate for the use of comprehensive

serologies in the evaluation of new patients with interstitial lung disease and the inclusion of

rheumatologists as part of the multi-disciplinary team discussion of ILD patients.

274

This study has several limitations. First, a cross-sectional design at a single center resulted in a limited sample size, which precluded comparisons between some IIM-ILD groups. Additionally, not all CT scans used in this study were high-resolution, which is considered gold standard for the classification of ILD patterns. Further, the use of retrospective chart abstractions meant that not all patients had a complete dataset, and data on objective muscle weakness across the entire clinical course was not available. While comprehensive myositis serologies are clearly useful for identifying ARS-ILD, the yield of comprehensive myositis screening in a tertiary ILD clinic is unclear.

In conclusion, ARS patients without prominent extra-pulmonary manifestations are at high risk for not being recognized as having an alternative etiology and miscategorized as UIP/IPF in the absence of

290	comprehensive serologies.	Future work is required to (1)	quantify the benefit instituting	comprehensive
-----	---------------------------	--------------------------------	----------------------------------	---------------

- serologies and rheumatologic consultation in the care of ILD patients at a tertiary care center and (2)
- 292 determine if obtaining comprehensive myositis serologies improves patient outcomes.
- 293
- Acknowledgements: This work was supported by CTSA award No. UL1TR000445 (EMW) from the
- 295 National Center for Advancing Translational Sciences, the National Institutes of Health T32HL087738
- 296 (EMW), T32AR0590139 (JJY), K08AR072757 (AB), Vanderbilt Faculty Research Scholars Award
- 297 (EMW), and the Porter Family Fund for Autoimmunity Research. The contents are solely the
- 298 responsibility of the authors and do not necessarily represent official views of the National Center for
- 299 Advancing Translational Sciences or the National Institutes of Health.
- 300
- 301

302 References

Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). *N Engl J Med* 1975:
 292(7): 344-347.

Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, Oddis CV. Patients with
 non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. *Ann Rheum Dis* 2014: 73(1): 227-232.

308 3. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, Silhan L,

309 Christopher-Stine L, Mammen AL, Danoff SK. A longitudinal cohort study of the anti-synthetase

310 syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and

anti-PL12 autoantibodies. *Rheumatology (Oxford)* 2017: 56(6): 999-1007.

4. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V,

313 Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK,

Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL,

Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson

316 KC, American Thoracic Society ERSJRS, Latin American Thoracic S. Diagnosis of Idiopathic

317 Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care

318 *Med* 2018: 198(5): e44-e68.

5. Hoffmann-Vold A-M, Gunnarsson R, Garen T, Midtvedt Ø, Molberg Ø. Performance of the 2013

320 American College of Rheumatology/European League Against Rheumatism Classification Criteria for

321 Systemic Sclerosis (SSc) in Large, Well-defined Cohorts of SSc and Mixed Connective Tissue Disease.

322 The Journal of Rheumatology 2015: 42(1): 60-63.

323 6. Aggarwal R, Dhillon N, Fertig N, Koontz D, Qi Z, Oddis CV. A Negative Antinuclear Antibody

324 Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening

325 Test for Antisynthetase Syndrome. *J Rheumatol* 2017: 44(2): 223-229.

Juu Q, Day J, Hall A, Limaye V, Major G. External Validation and Evaluation of Adding MRI or
 Extended Myositis Antibody Panel to the 2017 EULAR/ACR Myositis Classification Criteria. *ACR Open Rheumatology* 2019: 1(7): 462-468.

329 8. Greco M, García de Yébenes MJ, Alarcón I, Brandy-García AM, Rúa-Figueroa Í, Loza E,

330 Carmona L. Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of

331 antisynthetase antibodies to improve current classification criteria. Annals of the Rheumatic Diseases

332 **2019: 78(9): 1291-1292.**

333 9. Knitza J, Cavagna L, Schett G, Distler JHW. Comment on: 'Idiopathic inflammatory myopathies

and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification

criteria' by Greco et al. Annals of the Rheumatic Diseases 2020: 79(7): e85-e85.

10. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA,

Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K,

Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA,

Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A,

340 Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, International Myositis Classification Criteria

341 Project consortium TEr, The Juvenile Dermatomyositis Cohort Biomarker S, Repository. 2017

342 European League Against Rheumatism/American College of Rheumatology classification criteria for

adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis

344 2017: 76(12): 1955-1964.

11. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with
the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? *Chest*2010: 138(6): 1464-1474.

12. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M,

Naden RP, Medsger TA, Jr., Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O,

Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M,

351 Kowal-Bielecka O, Muller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH,

- 352 Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski
- 353 S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an
- 354 American College of Rheumatology/European League against Rheumatism collaborative initiative.
- 355 *Arthritis Rheum* 2013: 65(11): 2737-2747.
- 13. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in
- 357 patients with interstitial lung disease. *Chest* 1999: 116(5): 1175-1182.
- 14. Papiris SA, Daniil ZD, Malagari K, Kapotsis GE, Sotiropoulou C, Milic-Emili J, Roussos C. The
- Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary
 fibrosis. *Respir Med* 2005: 99(6): 755-761.
- 15. Cavagna L, Nuno L, Scire CA, Govoni M, Longo FJ, Franceschini F, Neri R, Castaneda S,
- 362 Sifuentes Giraldo WA, Caporali R, Iannone F, Fusaro E, Paolazzi G, Pellerito R, Schwarting A,
- 363 Saketkoo LA, Ortego-Centeno N, Quartuccio L, Bartoloni E, Specker C, Murcia TP, La Corte R, Furini
- 364 F, Foschi V, Corral JB, Airo P, Cavazzana I, Martinez-Barrio J, Hinojosa M, Giannini M, Barsotti S,
- Menke J, Triantafyllias K, Vitetta R, Russo A, Bajocchi G, Bravi E, Barausse G, Bortolotti R, Selmi C,
- 366 Parisi S, Montecucco C, Gonzalez-Gay MA, group Ac. Clinical Spectrum Time Course in Anti Jo-1
- 367 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study.
- 368 *Medicine (Baltimore)* 2015: 94(32): e1144.
- 16. Aggarwal R, McBurney C, Schneider F, Yousem SA, Gibson KF, Lindell K, Fuhrman CR, Oddis
- 370 CV. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary
- 371 fibrosis. *Rheumatology (Oxford)* 2017: 56(3): 384-389.
- 17. Liu H, Xie S, Liang T, Ma L, Sun H, Dai H, Wang C. Prognostic factors of interstitial lung
 disease progression at sequential HRCT in anti-synthetase syndrome. *European Radiology* 2019:
 29(10): 5349-5357.
- 18. Debray MP, Borie R, Revel MP, Naccache JM, Khalil A, Toper C, Israel-Biet D, Estellat C, Brillet
 PY. Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. *Eur J Radiol*2015: 84(3): 516-523.

19. Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, Handa T, Mishima M, 378 379 Hirakata M, Takeuchi T, Fujio K, Yamamoto K, Kohsaka H, Takasaki Y, Enomoto N, Suda T, Chida K, Hisata S, Nukiwa T, Mimori T. The multicenter study of a new assay for simultaneous detection of 380 381 multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One 2014: 9(1): 382 e85062. Levi Y, Israeli-Shani L, Kuchuk M, Epstein Shochet G, Koslow M, Shitrit D. Rheumatological 383 20. 384 Assessment Is Important for Interstitial Lung Disease Diagnosis. The Journal of Rheumatology 2018: 385 45(11): 1509-1514. 21. Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ, 386 Sanyal A, Mammen AL, Christopher-Stine L, Danoff SK. Long-Term Treatment With Azathioprine and 387 388 Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. Chest 2019: 156(5): 896-906. 389 22. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider 390 LG, Harris-Love MO, Levesque MC, Group RIMS, Oddis CV. Predictors of clinical improvement in 391 rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014: 66(3): 740-749. 392 393 23. Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, Fujieda Y, Oku K, Bohgaki T, 394 Amengual O, Horita T, Atsumi T. The efficacy of tacrolimus in patients with interstitial lung diseases 395 complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 2015: 54(1): 39-44. 396 24. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of 397 antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis & Rheumatism: Official 398 Journal of the American College of Rheumatology 2005: 52(8): 2439-2446. Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, Roblot P, Jouneau S, Hatron PY, 399 25. 400 Tiev KP, Vittecog O, Noel D, Mouthon L, Menard JF, Jouen F. Comparison of long-term outcome 401 between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmunity 402 *Reviews* 2012: 11(10): 739-745.

- 403 26. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-404 isoleucyl-tRNA synthetase) autoantibodies. *Rheumatology* 2007: 46(5): 842-845.
- 405 27. Carlos de Souza FH, Pina Cruellas MG, Levy-Neto M, Shinjo SK. Anti-synthetase syndrome:
- 406 anti-PL-7, anti-PL-12 and anti-EJ. *Revista Brasileira de Reumatologia (English Edition)* 2013: 53(4):

407 352-357.

- 408 28. Giannini M, Notarnicola A, Dastmalchi M, Lundberg IE, Lopalco G, Iannone F. Heterogeneous
- 409 clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case
- 410 series. *Clinical Rheumatology* 2016: 35(9): 2363-2367.
- 411 29. Schneider F, Yousem SA, Bi D, Gibson KF, Oddis CV, Aggarwal R. Pulmonary pathologic

412 manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy. *Journal of*

- 413 *Clinical Pathology* 2014: 67(8): 678-683.
- 414 30. Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramírez R, Jara LJ, Saavedra MA, Cruz-
- 415 Gonzalez C, Andrade-Ortega L, Vera-Lastra O, Salazar-Páramo M, Prieto-Parra RE, Gonzalez-Lopez
- 416 L, Gamez-Nava JI, Ramírez-Sánchez HU, Chan JYF, Ross SJ, Chan EKL, Vázquez-Del Mercado M.
- 417 Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two
- dermatomyositis cohorts from Mexico City and Guadalajara. *Arthritis Research & Therapy* 2013: 15(2):
- 419 R48.
- 420 31. Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK,
- Johnson C, Christopher-Stine L, Mammen AL. Antinuclear Matrix Protein 2 Autoantibodies and Edema,
- 422 Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care & Research 2017:
- 423 69(11): 1771-1776.
- 424 32. Yang H, Lu X, Peng Q, Jiang W, Shi J, Zhang Y, Chen H, Wang G. Differential Clinical
- 425 Associations of Anti–Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory
- 426 Myopathies. *Arthritis & Rheumatology* 2018: 70(8): 1288-1297.
- 427 33. Cuesta-Mateos C, Colom-Fernández B, Portero-Sainz I, Tejedor R, García-García C, Concha-
- 428 Garzón MJ, De las Heras-Alonso ME, Martínez MA, Juarez C, Muñoz-Calleja C. Autoantibodies against

TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical
significance and diagnostic utility. *Journal of the European Academy of Dermatology and Venereology*2015: 29(3): 482-489.

432 34. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WER, Cooper RG, McHugh NJ.

433 Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small

434 ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-

435 onset myositis. Annals of the Rheumatic Diseases 2009: 68(10): 1621-1625.

436 35. Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik JJ, Danoff SK, Casciola-Rosen L,

437 Christopher-Stine L, Mammen AL. Longitudinal Course of Disease in a Large Cohort of Myositis

438 Patients With Autoantibodies Recognizing the Signal Recognition Particle. *Arthritis Care & Research*

439 2017: 69(2): 263-270.

440 36. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma Differentiation-

441 associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with

442 Dermatomyositis. *The Journal of Rheumatology* 2017: 44(3): 319-325.

443 37. Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airò P, Cattaneo R, Franceschini F.

444 Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. *Lupus*445 2008: 17(8): 727-732.

446 38. Casal-Dominguez M, Pinal-Fernandez I, Corse AM, Paik J, Albayda J, Casciola-Rosen L,

Johnson C, Danoff SK, Christopher-Stine L, Tiniakou E, Mammen AL. Muscular and extramuscular

features of myositis patients with anti-U1-RNP autoantibodies. *Neurology* 2019: 92(13): e1416-e1426.

449 39. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger Jr. TA. Anti–U3 RNP autoantibodies in

450 systemic sclerosis. *Arthritis & Rheumatism* 2009: 60(4): 1112-1118.

451 40. De Lorenzo R, Pinal-Fernandez I, Huang W, Albayda J, Tiniakou E, Johnson C, Milisenda JC,

452 Casal-Dominguez M, Corse AM, Danoff SK, Christopher-Stine L, Paik JJ, Mammen AL. Muscular and

453 extramuscular clinical features of patients with anti-PM/Scl autoantibodies. *Neurology* 2018: 90(23):

454 e2068-e2076.



456 **Figure 1.** Time to diagnosis for patients with ARS-ILD (n=21) compared to DM/PM-ILD (n=14). Violin

457 plots show the range with interquartile range. Mann-Whitney U-tests shown.



459

Figure 2. Physiologic features of IIM-ILD comparaed to SSc-ILD. (A) Patients with ARS have more
 severe restriction than DM or IcSSc and similar restriction compared to dcSSc. (B) There is no
 significant difference in diffusion impairment amongst IIM or SSc subsets. Box plots depict median ±
 IQR, KW=Kruskal-Wallis, Mann-Whitney U-test *p<0.05, **p<0.01.



- 466 **Figure 3.** Stratification of physiologic impairment according to American Thoracic Society criteria. The
- 467 severity of impairment of (A) FVC and (B) DLCO for IIM and SSc subsets are shown.

Table 1. Clinical manifestations of various myositis specific and associated autoantibodies

	Autoantibody	Clinical features	Freque	ncy of organ invo	olvement
			Skin	Muscle	Lung
	Jo-1[3, 25]	Classic dermatomyositis with typical rash, muscle weakness, ILD, and mechanic's hands	30-58%	69.3-86%	68%-95%
Anti-tRNA	PL-7 [3, 25]		29-56%	40-81%	>90%
synthetase	PL-12 [3, 25]	Hypomyopathic myositis with frequent arthritis,	29-70%	40-69%	>90%
syndrome	OJ [26]	mechanic's hands, and ILD	0%	57%	100%
	EJ [27-29]		0-75%	0-100%	50-100%
	Mi-2 [30]	Classical rash with mild to moderate muscle involvement, ILD uncommon	90%	100%	7%
	NXP-2 [31, 32]	Mild to moderate muscle involvement with myalgia, dysphagia, classical skin rashes, increased malignancy risk, can be associated with ILD	17-32%	>95%	7-25%
Other myositis specific	TIF-1γ [33]	Marked skin involvement often with ulceration, muscle weakness, dysphagia, malignancy	>90%	63%	9.1%
autoantibodies	SAE [34]	Classic skin rashes associated with mild to moderate weakness, ILD uncommon	>80%	>95%	18%
	SRP [35]	Necrotizing myopathy with marked weakness, minimal skin involvement, and infrequent ILD	3%	>90%	22%
	MDA5 [36]	Frequent and severe ILD with minimal or no muscle involvement and classically ulcerative skin lesions or palmar papules.	87.5%	50%	50%
	Ku [37]	Overlap syndrome of systemic sclerosis and inflammatory myositis with mild muscle/skin involvement and variable ILD severity	n.r.	30%	43%
Overlap syndrome	U1RNP [38]	Overlap syndrome of systemic lupus, systemic sclerosis, and inflammatory myositis	60%	80%	45%
	U3RNP [39]	Diffuse systemic sclerosis with increased frequency of inflammatory myopathy	>95%	25%	61%
	Pm/Scl [40]	Mild myositis and/or systemic sclerosis features frequently with ILD	85%	38%	61%
Abbreviations: ILD=i	nterstitial lung disease	•		<u>I</u>	<u>I</u>

*ILD more common in patients with inflammatory myositis compared to other Ku positive patients

Table 2. Demographics

	Idiopathic Inflammatory	Systemic Sclerosis	p value
	Myopathies (n=77)	(n=47)	
Age (years) [↑]	57.7(48.4,66.7)	62.3(52.3,69.0)	.0.13
Female Gender	60 (77.9%)	37 (78.7%)	1.00
Race			
Caucasian	63 (81.8%)	37 (78.7%)	0.82
African American	11 (14.2%)	7 (14.9%)	1.00
Other	3 (3.9%)	3 (6.4%)	0.67
Disease Duration (years) [†]	5.2(2.4,10.4)	9.5(4.8,14.6)	0.007
Known Presence of ILD	40 (51.9%)	28 (59.5%)	0.46
Radiographic and physiologic evidence of ILD	33/40 (82.5%)	20/28 (71.4%)	0.37
Radiographic evidence of ILD with normal	2/40 (5.0%)	1/28 (3.6%)	1.00
PFTs			
Physiologic evidence of ILD with normal	5/40 (12.5%)	6/28 (21.4%)	0.34
imaging			
Historic documentation without objective data	0/40	1/28 (3.6%)	1.00
Known Presence of Pulmonary Hypertension	8 (20%)	17 (36.1%)	0.001
Pulmonology as First Point of Care at VUMC	22 (28.5%)	13 (27.6%)	1.00
[†] reported as median (interquartile range)			
Abbreviations: ILD=interstitial lung disease, PFTs=pulm	nonary function tests, VUMC=Vande	erbilt University Medical Center	

Table 3. Clinical	Phenotype of	Idiopathic	Inflammatory	Myopathies	Patients
				,	

									Dysphagia	Raynaud's
	Associated Serologies		Cutaneous Ma	anifestations	Muscle Inv	volvement	Arthritis	or GERD	Phenomenon	
				Gottron's or		Proximal	Muscle			
				Heliotrope	Mechanic's	Muscle	Enzyme			
	ANA	RF	Ro52	Rash	Hands	Weakness	Elevation			
By Clinical										
Phenotype*										
Dermatomyositis	25/31	4/17	8/12	33/37	9/37	27/37	29/37	10/37	11/37	14/37
(n=37)	(80.6%)	(23.5%)	(40.0%)	(89.1%)	(24.3%)	(73.0%)	(78.3%)	(27.0%)	(29.8%)	(37.8%)
Polymyositis	6/10	2/5	0/6	0/12	0/12	12/12	11/12	1/12	8/12	2/12
(n=12)	(60.0%)	(40.0%)	(0%)	(0%)	(0%)	(100%)	(91.7%)	(8.3%)	(66.7%)	(16.7%)
Anti-Synthetase	9/25	4/21	14/22	6/28	12/28	18/28	21/28	17/28	13/28	10/28
Syndrome	(36.0%)	(19.0%)	(63.6%)	(21.4%)	(43.8%)	(64.3%)	(75.0%)	(60.7%)	(46.4%)	(35.7%)
(n=28)										
By Serology										
Jo-1	3/11	2/10	5/9	2/14	8/14	12/14	12/14	13/14	7/14	6/14
(n=14)	(27.2%)	(20%)	(55.6%)	(14.3%)	(57.1%)	(85.6%)	(85.6%)	(92.9%)	(50%)	(42.9%)
PL-7	2/5	1/5	3/5	1/5	2/5	2/5	2/5	1/5	3/5	1/5
(n=5)	(40.0%)	(20.0%)	(60.0%)	(20.0%)	(40.0%)	(60.0%)	(40.0%)	(20.0%)	(60.0%)	(20.0%)
PL-12	1/5	1/4	4/6	3/6	1/1	3/6	5/6	1/6	3/6	2/6
(n=6)	(20.0%)	(14.3%)	(42.9%)	(50.0%)	(16.7%)	(50.0%)	(83.3%)	(16.7%)	(50.0%)	(33.3%)
EJ	0/1	0/0	1/1	0/1	0/1	0/1	1/1	1/1	1/1	0/1
(n=1)	(0%)	(0%)	(100%)	(0%)	(0%)	(0%)	(100%)	(100%)	(100%)	(0%)
OJ	1/2	0/0	1/1	0/2	1/2	1/2	1/2	1/2	1/2	1/2
(n=2)	(50.0%)	(0%)	(100%)	(0%)	(50.0%)	(50.0%)	(50.0%)	(50.0%)	(50.0%)	(50.0%)
Ku	2/2	0/1	2/2	1/2	0/2	1/2	2/2	0/2	1/2	0/2

(n=2)	(100%)	(0%)	(100%)	(50.0%)	(0%)	(50.0%)	(100%)	(0%)	(50.0%)	(0%)
NXP	3/3	0/2	1/2	2/3	0/3	2/3	3/3	0/3	1/3	0/3
(n=3)	(100%)	(0%)	(50.0%)	(66.7%)	(0%)	(66.7%)	(100.0%)	(0%)	(33.3%)	(0%_
TIF1g	1/1	0/0	0/1	1/1	0/1	1/1	1/1	0/1	1/1	0/1
(n=1)	(100%)	(0%)	(0%)	(100%)	(0%)	(100%)	(50.0%)	(0%)	(100%)	(0%)
Pm/Sc	d 4/4	2/2	2/4	3/4	3/4	4/4	4/4	2/4	3/4	0/4
(n=4)	(100%)	(100%)	(50.0%)	(75.0%)	(75.0%)	(100%)	(100%)	(50.0%)	(75.0%)	(0%)
SRP	0/2	0/1	0/2	0/2	0/2	2/2	2/2	0/2	2/2	0/2
(n=2)	(0%)	(0%)	(0%)	(0%)	(0%)	(100%)	(100%)	(0%)	(100%)	(0%)
Mi2	5/5	0/1	1/3	5/5	2/5	5/5	5/5	1/5	1/5	3/5
(n=5)	(100%)	(0%)	(33.3%)	(100%)	(40.0%)	(100.0%)	(10.0%)	(20%)	(20%)	(40%)
			All 12 1 11	CONTRACTOR			1 1 11			

*These are non-overlapping phenotypes. All patients with anti-tRNA synthetase antibodies were categorized as anti-synthetase syndrome.

Abbreviations: ANA=anti-nuclear antibodies, RF=rheumatoid factor, GERD=gastroesophageal reflux disease

				Diagnostic yield after	Diagnostic yield after	Diagnostic yield after
	+ANA	+RF	+CCP	initial serologic work-up	testing CK level	adding MSA/MAA [†]
Dermatomyositis	11/12	3/6	2/4	13/15	13/15	13/15
(n=15)	(86.7%)	(50.0%)	(50.0%)	(86.7%)	(86.7%)	(86.7%)
Polymyositis	1/3	1/3	1/2	1/3	3/3	3/3
(n=3)	(33.3%)	(33.3%)	(50%)	(33.3%)	(100%)	(100%)
Anti-synthetase	5/20	4/18	0/13	7/21	16/22	22/22
Syndrome	(25.0%)	(22.2%)	(0%)	(33.3%)	(72.7%)	(100%)
(n=22)						

Table 4. Comprehensive myositis serologies play a critical role in the serologic detection of ARS-ILD compared to other IIM-ILD

† MSA = myositis specific antibodies (Jo-1, PL-7, PL-12, OJ, EJ, Mi-2, SRP, TIF-1γ, MJ/NXP-2, SAE, MDA-5/CADM-140; MAA =

myositis associated antibodies (Pm/Scl, Ku, U1RNP, U3RNP, Ro52)

Abbreviations: ARS-ILD=anti-tRNA synthetase related interstitial lung disease, IIM-ILD idiopathic inflammatory myopathies associated interstitial lung disease, ANA=anti-nuclear antibodies, RF=rheumatoid factor, CCP=anti-cyclic citrullinated peptide, CK=creatinine kinase,

Table 5. Radiographic features of interstitial lung disease in patients

with IIM compared to SSc

	Radiographic Characteristics						
	UIP	GGO	BC	HC			
Inflammatory Myo	ositis						
Dermatomyositis	1/13	10/13	4/13	1/13			
(n=15)	(7.7%)	(76.9%)	(30.8%)	(7.7%)			
Polymyositis	0/3	2/3	0/3	0/3			
(n=3)	(0%)	(66.7%)	(0%)	(0%)			
Anti-Synthetase	5/22	12/22	11/22	3/22			
Syndrome	(22.7%)	(54.5%)	(50%)	(13.6%)			
(n=22)							
By Serology							
Jo-1	2/10	9	7/10	12			
(n=10)	(20%)	(90%)	(70.0%)	(20.0%)			
PL-7	1	3	4	3			
(n=5)	(20%)	(60%)	(80%)	(60%)			
PL-12	1	4	4	1			
(n=5)	(20.0%)	(80%)	(80%)	(20%)			
EJ	0	0	0	0			
(n=1)	(0%)	(0%)	(0%)	(0%)			
OJ	0	1	0	0			
(n=1)	(0%)	(100%)	(0%)	(0%)			
Ku	0	1/2	0	0			
(n=2)	(0%)	(50%)	(0%)	(0%)			
NXP	0	1	1	0			
(n=1)	(0%)	(100%)	(100%)	(0%)			
Pm/Scl	0	3/3	1/3	0			
(n=3)	(0%)	(100%)	(33.3%)	(0%)			
SRP	0	0	0	0			
(n=1)	(0%)	(0%)	(0%)	(0%)			
Mi2	0	1	1	0			
(n=1)	(0%)	(100%)	(100%)	(0%)			
Systemic Scleros	is						

16886	3/15	0/15	8/15	5/15
1.000	5/15	9/13	0/15	5/15
(n=18)	(20%)	(60%)	(53.3%)	(33.3%)
()	()	(00,0)	()	(
dcSSc	1/9	8/9	6/9	5/9
(n=10)	(11.1%)	(88.9%)	(66.7%)	(55.6%)

Abbreviations: IIM=idiopathic inflammatory myopathies,

SSc=systemic sclerosis, UIP = usual interstitial pneumonia (definite

or probable), GGO = ground glass opacities, BC = bronchiectasis,

HC = honeycomb changes, IcSSc=limited cutaneous systemic

sclerosis, dcSSc=diffuse cutaneous systemic sclerosis